In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Oncologic Drugs Advisory Committee

Executive Summary

Oncologic Drugs Advisory Committee: Janssen's Liazal (liarozole fumarate, NDA 27-094) will be reviewed the morning of June 24 for treatment of advanced prostate cancer. On June 23, committee will consider Ilex' Zyrkamine (mitoguazone, NDA 20-709) for treatment of AIDS-related non-Hodgkin's lymphoma and Bristol-Myers Squibb's Taxol (paclitaxel, NDA 20-262) for second-line treatment of AIDS-related Kaposi's sarcoma. The meeting will take place at the Holiday Inn-Bethesda, Md. beginning 8:30 a.m. on June 23 and 9 a.m. June 24...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts